Retreatment with venetoclax and rituximab in CLL patients achieved 100% response rates and prolonged progression-free survival. This new study reveals venetoclax and rituximab effectively treat ...

MRD-guided therapy for CLL balances treatment cessation risks with cumulative toxicity concerns, offering a promising alternative to continuous or fixed-duration therapies. The VISION/HOVON141 trial ...

The episode focuses on the refinement of CLL therapy, moving away from traditional chemoimmunotherapy toward targeted approaches. Highlights include: Continuous vs. fixed-duration therapy: A debate on ...

New data demonstrate the actionability of clonoSEQ for tailoring treatment decisions in patients with MCL, CLL, MM and ALL Studies show depth of response at 10-6 provides more accurate assessment of ...

Suchitra Sundaram, MD, describes the excitement around the American Society of Hematology (ASH) 2024 meeting in the chronic lymphocytic leukemia (CLL) community, with promising updates on innovative ...

Please provide your email address to receive an email when new articles are posted on . Patients who achieved undetectable measurable residual disease had a 72% reduced risk for disease progression or ...

Suchitra Sundaram, MD, reviews new data on CLL treatments presented at ASH 2024, highlighting exciting possibilities for future patient care. She recounts the case of a 75-year-old man with worsening ...

MRD quantification allows for improved PFS prediction in both patients who achive PR and CR, which thus supports its application in all responders. In contrast to residual lymphadenopathy, persisting ...

Developments in chronic lymphocytic leukemia (CLL) this year included the first CAR T-cell therapy approval for the chronic blood cancer, potential treatments for Richter transformation, and ...

Ibrutinib, an inhibitor of Bruton’s tyrosine kinase, and venetoclax, an inhibitor of B-cell lymphoma 2 protein, have been approved for patients with chronic lymphocytic leukemia (CLL). Preclinical ...